Urothelial Carcinoma (UC) Clinical Trials

6 recruiting

Urothelial Carcinoma (UC) Trials at a Glance

6 actively recruiting trials for urothelial carcinoma (uc) are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 2 trials, with the heaviest enrollment activity in Dijon, Fairfax, and Fort Worth. Lead sponsors running urothelial carcinoma (uc) studies include IDEAYA Biosciences, IRCCS San Raffaele, and ITM Oncologics GmbH.

Browse urothelial carcinoma (uc) trials by phase

Treatments under study

About Urothelial Carcinoma (UC) Clinical Trials

Looking for clinical trials for Urothelial Carcinoma (UC)? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Urothelial Carcinoma (UC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Urothelial Carcinoma (UC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Not Applicable

Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA

Bladder CancerOligometastasisUrothelial Carcinoma (UC)
Istituto Clinico Humanitas44 enrolled1 locationNCT07413523
Recruiting
Phase 1

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Gastric AdenocarcinomaBladder CancerMesothelioma+7 more
IDEAYA Biosciences260 enrolled10 locationsNCT07277413
Recruiting

Korean Prospective Upper Tract Urothelial Carcinoma Cohort

Urothelial Carcinoma (UC)
Samsung Medical Center300 enrolled1 locationNCT07452432
Recruiting

Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma

Urothelial Carcinoma (UC)Bladder (Urothelial, Transitional Cell) CancerLiquid Biopsy
Tianjin Medical University Second Hospital300 enrolled1 locationNCT07441499
Recruiting
Phase 1Phase 2

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)Clear Cell Renal Cell Cancer (ccRCC)+4 more
ITM Oncologics GmbH270 enrolled10 locationsNCT05706129
Recruiting

A Patient-Directed Mobile Tool to Streamline the QoL Assessment and Monitoring in Urothelial Carcinoma

Urothelial Carcinoma (UC)
IRCCS San Raffaele50 enrolled1 locationNCT06982794